Lilly Sues Hetero To Block Generic Strattera

Law360, New York (June 9, 2011, 1:06 PM EDT) -- Eli Lilly & Co. filed suit in New Jersey on Monday in an effort to keep India's Hetero Drugs Ltd. from launching a generic version of attention deficit hyperactivity disorder treatment Strattera in the U.S.

Lilly launched its suit in response to Hetero's U.S. arm filing an abbreviated new drug application with the U.S. Food and Drug Administration for permission to market atomoxetine hydrochloride capsules, which Lilly brands as Strattera, before Lilly's patent for the drug expires.

The suit claims that Hetero's filing of the ANDA...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.